U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H32ClN5O3
Molecular Weight 461.985
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DASOLAMPANEL ETIBUTIL

SMILES

[H][C@@]12CC[C@@H](C[C@]1([H])C[C@H](NC2)C(=O)OCC(CC)CC)OC3=C(C4=NN=NN4)C(Cl)=CC=C3

InChI

InChIKey=HPBRMCFZIGUGTK-ZMMAXQRCSA-N
InChI=1S/C23H32ClN5O3/c1-3-14(4-2)13-31-23(30)19-11-16-10-17(9-8-15(16)12-25-19)32-20-7-5-6-18(24)21(20)22-26-28-29-27-22/h5-7,14-17,19,25H,3-4,8-13H2,1-2H3,(H,26,27,28,29)/t15-,16+,17-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H32ClN5O3
Molecular Weight 461.985
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dasolampanel (NGX-426) is an orally available competitive antagonist of the AMPA and kainate receptors. The dug originated at Eli Lilly and Horizon Pharma and was developed for the treatment of migraine and neuropathic pain. Dasalompanel was reduced capsaicin-induced pain and hyperalgesia in human volunteers but failed to achieve positive results in phase 2 clinical trials in patients with pain due to osteoarthritis of the knee and diabetic peripheral neuropathic pain.

Originator

Approval Year

Substance Class Chemical
Record UNII
M7BFC308LR
Record Status Validated (UNII)
Record Version